drugset / Trial / NCT03646604

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Participants With Severe Atopic Dermatitis

NCT03646604

Phase 1 Completed 35 enrolled AbbVie
Non-randomizedSequentialOpen-labelTreatment

Summary

The objective of this study is to evaluate the safety, pharmacokinetics and tolerability of multiple doses of upadacitinib in pediatric participants with severe atopic dermatitis and to evaluate palatability of upadacitinib oral solution in pediatric participants.

Timeline

Start
2019-01-31
Primary completion
2024-08-29
Completion
2024-08-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Upadacitinib Small molecule Oral

Indications